US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
62 deals · US$14bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Dec 2025 | Apimeds Pharmaceuticals US | – | – | Convertible | Completed | 10.9 | Pharma+1 | Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager) |
| Jan 2026 | Aktis Oncology | – | – | IPO | Listed | 317.7 | Biotech+2 | Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager) |
| Jan 2026 | Polaryx Therapeutics | – | – | Direct listing | Completed | – | Biotech+1 | Maxim Group (issuer)Gibson Dunn (issuer)Brownstein Hyatt Farber Schreck (issuer) |
| Feb 2026 | Perspective Therapeutics | – | – | Follow-on offering | Announced | 175.0 | Radiopharmaceuticals+2 | Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager) |
| Feb 2026 | Veradermics | – | – | IPO | Announced | 256.3 | Dermatology+2 | Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager) |
| Feb 2026 | Eikon Therapeutics | – | – | IPO | Announced | 381.2 | Oncology+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager) |
| Feb 2026 | Agomab Therapeutics NV | – | – | IPO | Announced | 200.0 | Biotech+2 | Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager) |
| Feb 2026 | Liminatus Pharma | – | – | Follow-on offering | Announced | 4.0 | Biotech+2 | Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager) |
| Feb 2026 | Sensei Biotherapeutics | – | – | Placement | Pending | 200.0 | Biotech+2 | Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager) |
| Feb 2026 | Generate Biomedicines | – | – | IPO | Listed | 400.0 | Biotech+2 | Goodwin (issuer)Goldman Sachs (lead manager)Morgan Stanley (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager) |
| Mar 2026 | Candid Therapeutics | – | – | Placement | Pending | 505.0 | Biotech+1 | Cooley (issuer)Jefferies (lead manager)BofA Securities (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager) |
| Mar 2026 | Pulmatrix | – | – | Placement | Announced | 19.0 | Biotech | Palladium Capital Group (lead manager) |
| Apr 2026 | Korsana Biosciences | – | – | Placement | Announced | 380.0 | Biotech+1 | Cooley (lead manager) |
| Apr 2026 | Obsidian Therapeutics | – | – | Placement | Completed | 350.0 | Biotech+2 | GoodwinSidley Austin (issuer)Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)LifeSci Capital (lead manager)Mintz (lead manager) |
| Apr 2026 | Kailera Therapeutics | – | – | IPO | Announced | 625.0 | Biotech+1 | Latham & Watkins (issuer)William Blair (lead manager)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Evercore (lead manager)Paul Hastings (lead manager) |
| Apr 2026 | Opus Genetics | – | – | Placement | Announced | 5.0 | Biotech+1 | Sidley Austin (issuer) |
| Apr 2026 | Avalyn Pharma | – | – | IPO | Listed | 300.0 | Biotech+2 | Goodwin (issuer)Morgan Stanley (lead manager)Jefferies (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Davis Polk (lead manager) |
| Apr 2026 | Hemab Therapeutics Holdings | – | – | IPO | Announced | 301.5 | Biotech+1 | WilmerHale (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Wedbush Securities (lead manager)Goodwin (lead manager) |
| Apr 2026 | Seaport Therapeutics | – | – | IPO | Announced | 254.9 | Biotech+1 | Goodwin (issuer)Goldman Sachs (lead manager)J.P. Morgan (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager) |
| May 2026 | Odyssey Therapeutics | – | – | IPO | Announced | 279.0 | Biotech+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager) |
| May 2026 | Odyssey Therapeutics | – | – | Placement | Pending | 25.0 | Biotech+1 | J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager) |
| May 2026 | Quince Therapeutics | – | – | Placement | Announced | 115.0 | Biotech+2 | EvercoreCantor FitzgeraldLifeSci Capital (lead manager)Gibson Dunn (lead manager) |
| May 2026 | Mentari Therapeutics | – | – | Placement | Announced | 290.0 | Biotech+1 | Gibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Guggenheim Securities (lead manager)Wedbush Securities (lead manager) |
| May 2026 | Optimi Health Corp. | – | – | Follow-on offering | Announced | 15.0 | Biotech+2 | Norton Rose Fulbright (issuer)Joseph Gunnar & Co. (lead manager)Cozen O'Connor (lead manager) |
| Jun 2026 | Avenzo Therapeutics | – | – | Placement | Pending | 215.0 | Biotech+2 | Leerink Partners (lead manager)Goldman Sachs (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Mintz (lead manager) |
| Jun 2026 | Parabilis Medicines | – | – | IPO | Listed | 670.0 | Biotech+2 | Goodwin (issuer)Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)Covington & Burling (lead manager) |
| Jun 2026 | Adial Pharmaceuticals | – | – | Placement | Pending | 32.0 | Biotech+1 | TD Securities (issuer)Lucid Capital Markets (lead manager) |
| Jun 2026 | Parabilis Medicines | – | – | Placement | Completed | 75.0 | Biotech+1 | Goodwin (issuer) |
| Jun 2026 | Kardigan | – | – | IPO | Listed | 400.0 | Biotech+2 | Goodwin (issuer)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Latham & Watkins (lead manager) |
| Jun 2026 | Remix Therapeutics | – | – | Placement | Pending | 100.0 | Biotech+2 | Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Cooley (lead manager) |
| Jun 2026 | JATT II Acquisition Corp | – | – | Placement | Announced | 225.0 | Biotech+1 | Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)LifeSci Capital (lead manager)Davis Polk (lead manager) |
| Jul 2026 | BridgeBio Pharma | – | – | Placement | Announced | 1,000.0 | Biotech+1 | EvercoreSullivan & CromwellMintzGibson DunnLatham & Watkins (issuer) |
| Jul 2026 | Avere Therapeutics | – | – | Placement | Announced | 320.0 | Biotech+1 | Sullivan & CromwellGibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)Wedbush Securities (lead manager) |
| Jul 2026 | Jasper Therapeutics | – | – | Placement | Announced | 132.0 | Biotech+1 | Piper Sandler (lead manager)LifeSci Capital (lead manager) |
| Jul 2026 | Codexis | – | – | Follow-on offering | Completed | – | Biotech+1 | Piper Sandler (lead manager) |
| Jul 2026 | Scribe Therapeutics | – | – | IPO | Listed | 128.7 | Biotech+1 | Fenwick & West (issuer)Leerink Partners (lead manager)Goldman Sachs (lead manager)Guggenheim Securities (lead manager)Wells Fargo Securities (lead manager)Latham & Watkins (lead manager) |
| Jul 2026 | Research Alliance Corporation III | – | – | Placement | Announced | 100.0 | Biotech+2 | Leerink Partners (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)LifeSci Capital (lead manager)Kirkland & Ellis (lead manager) |
| Jul 2026 | Caldera Therapeutics | – | – | Placement | Announced | 278.0 | Biotech+1 | Jefferies (lead manager)TD Securities (lead manager)Guggenheim Securities (lead manager)UBS (lead manager)LifeSci Capital (lead manager)Cooley (lead manager) |
| Jul 2026 | Inovio Pharmaceuticals | – | – | Follow-on offering | Completed | – | Biotech+1 | Piper Sandler (issuer) |
| Jul 2026 | Processa Pharmaceuticals | – | – | Placement | Announced | 200.0 | Biotech+1 | Leerink Partners (lead manager)Evercore (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)Mintz (lead manager) |
| Jul 2026 | Apnimed | – | – | IPO | Listed | 192.0 | Biotech+1 | Goodwin (issuer)BofA Securities (lead manager)Evercore (lead manager)Cantor Fitzgerald (lead manager)LifeSci Capital (lead manager)Cleary Gottlieb Steen & Hamilton (lead manager) |
| Aug 2026 | BlossomHill Therapeutics | – | – | IPO | Listed | 150.0 | Biotech+2 | Cooley (issuer)J.P. Morgan (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)H.C. Wainwright & Co. (lead manager)Latham & Watkins (lead manager) |
| Aug 2026 | Latigo Biotherapeutics | – | – | IPO | Listed | 345.6 | Biotech+2 | Cooley (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)Latham & Watkins (lead manager) |
| Aug 2026 | Attovia Therapeutics | – | – | IPO | Listed | 289.0 | Biotech+1 | Fenwick & West (issuer)Morgan Stanley (lead manager)Leerink Partners (lead manager)Citi (lead manager)RBC Capital Markets (lead manager)LifeSci Capital (lead manager)Cooley (lead manager) |
| Aug 2026 | Braveheart Bio | – | – | IPO | Listed | 382.5 | Biotech+2 | Goodwin (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Cantor Fitzgerald (lead manager)Covington & Burling (lead manager) |
| Aug 2026 | Ensysce Biosciences | – | – | Placement | Announced | 43.0 | Biotech+1 | Cantor Fitzgerald (lead manager)UBS (lead manager)Mintz (lead manager) |
| Aug 2026 | Skye Bioscience | – | – | Placement | Announced | 68.0 | Biotech+1 | Leerink Partners (lead manager)MTS Health Partners (lead manager)Mintz (lead manager) |
| Aug 2026 | Silence Therapeutics | – | – | Placement | Completed | 201.0 | Biotech+1 | Goodwin (lead manager)Jefferies (lead manager)Morgan Stanley (lead manager)Cantor Fitzgerald (lead manager)William Blair (lead manager) |
| Aug 2026 | Slate Medicines | – | – | Placement | Announced | 245.0 | Biotech+1 | Cooley (issuer) |
| Aug 2026 | Ambros Therapeutics | – | – | Placement | Announced | 150.0 | Biotech+1 | Cooley (issuer) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built